- The company’s international partnerships expand its market reach and its line of recreational and medical cannabis products
- Supreme’s recent acquisition of Truverra Inc. gives it a foothold in the growing European market, as well as access to a 5,000-square-foot licensed facility in Ontario
- SPRWF’s research and development efforts supply agriculturally focused, disease-resistant, premium-seed stock to global markets
The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) operates with the mission of growing the world’s best cannabis and becoming a leader in the global industry. Supreme Cannabis has eyes on the expanding global market and has strategically positioned itself to be a leader in the space, with premium products, authentic brands and international investments.
SPRWF has entered into international partnerships to reach and meet the growing demand for recreational and medical cannabis. Khalifa Kush Enterprises (“KKE”) entered into an international partnership with SPRWF to develop and launch a lineup of premium cannabis. KKE Oils are created with premium cannabis supplied by 7ACRES, the flagship brand of SPRWF, and the line consists of recreational-focused offerings. The products are among the first-ever recreational-focused cannabis oils in Canada and became available earlier this year.
As global demand for medical cannabis oil grows, SPRWF also benefits from its investment in Medigrow Lesotho. The two companies entered into a long-term global distribution partnership in March 2018. Medical cannabis oil will be produced by Medigrow in Lesotho and then exported to Canada and additional international markets.
Closer to home, SPRWF recently closed on its acquisition of Toronto-based private company Truverra Inc. (http://ibn.fm/Tb0He). Selling CBD products through its subsidiary, Truverra (Europe) B. V., Truverra is dedicated to becoming a global leader of hemp- and cannabis-derived medicinal products with clinically proven efficacy. This acquisition only strengthens SPRWF’s position in the global cannabis market. Truverra is positioned to take advantage of the emerging CBD wellness market in Europe and is currently in the process of developing unique, cannabis-derived branded ingredients.
In addition to Truverra’s CBD business in Europe, Truverra’s Canadian subsidiary, Canadian Clinical Cannabinoids Inc. (“CCC”), operates a licensed facility in Ontario. “With the acquisition of Truverra, we secure a Toronto-based facility equipped to extract our high-quality inputs for concentrates and vaping liquids in the near-term,” SPRWF CEO Navdeep Dhaliwal stated in a news release referencing CCC’s 5,000-square-foot licensed facility that will be focused on producing cannabis-derivative extracts to be made available later this year (http://ibn.fm/FMQeV).
Truverra isn’t SPRWF’s only strategic move into the rapidly emerging European cannabis market. In June 2019, SPRWF launched London-based Supreme Heights as a separate entity. Supreme Heights is a CBD-focused investment platform that will make strategic investments in and provide support services to businesses in the CBD health and wellness segment. The goal is to support local UK and European businesses that share SPRWF’s core values of sustainability, innovation and community. This new entity will work to assess investment opportunities, identify synergies and advance businesses in its portfolio. Early-stage entrepreneurial companies will be assisted with capital and guidance in the development of innovative products.
Additionally, SPRWF maintains a strong position in Canada through its subsidiary and flagship brand, 7ACRES. 7ACRES is a licensed producer that operates a 440,000-square-foot facility in Ontario with a total licensed cultivation space of 230,000 square feet. From seed to shelf to consumer, 7ACRES prides itself on making every effort to cultivate a harvest greater than the previous in appearance, aroma and flavor. With a commitment to constantly improving techniques and practices, the company is leading the way toward a higher standard of cannabis. 7ACRES offers coast-to-coast distribution and is well on its way to becoming Canada’s leading cultivator of consistently superior cannabis.
In addition to partnerships, acquisitions and high end premium brands, SPRWF is leading the way in the development and licensing of next-generation, cannabis-plant genetics and cultivation IP. Cambium Plant Sciences was launched earlier this year to focus on supplying agriculturally focused, disease-resistant, premium-seed stock to the global cannabis market. Cambium’s 34,000-square-foot research and development facility in Goderich, Ontario, is using proprietary research, technology and scientific methodologies to revolutionize recreational, medical and wellness cannabis cultivation.
SPRWF continues to expand its global footprint through strategic partnerships, acquisitions and premium brands.
For more information, visit the company’s website at www.Supreme.ca
NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at http://ibn.fm/SPRWF